Posted on

Yale to study psilocybin for OCD

Ceruvia Lifesciences Submits FDA Investigational New Drug Application for Psilocybin Obsessive-Compulsive Disorder Program

Ceruvia Lifesciences submitted an application to study psilocybin as a treatment for obsessive-compulsive disorder (OCD) in a Phase 2 trial.

Preliminary findings suggest that psilocybin causes a “rapid and robust improvement in OCD symptoms with a sustained effect,” according to the press release.

The trial, which will be led by Yale researchers later this year if approval is granted, will determine if these findings hold true when psilocybin is compared to an active placebo. 

PDF of article

Posted on

MindMed advances ibogaine research after successful Phase 1 trial

MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal

This quarter, MindMed (MNMD) will begin a Phase 2a trial to see if its non-hallucinogenic ibogaine formulation (MM-110) can treat opioid withdrawal.

In preclinical research, MM-110 showed “multi-day reductions in opioid self-administration” after a single dose. 

In the Phase 1 trial, MM-110 was found to be safe and well-tolerated at varying doses. Some participants received two 325 mg doses on a single day while others received a 90 mg dose twice daily for 7 days.

Let’s see what Phase 2 reveals!

PDF of article

Posted on

Managing pain with MDMA

Global Wellness Readies for First Clinical Trial

Could your next surgery involve MDMA?

Shanti Therapeutics of Global Wellness Strategies (GWS) is preparing for a study to see if MDMA has an impact on pain tolerance in healthy volunteers.

The goal is to treat and prevent perioperative pain, or pain associated with surgery.

Managing pain immediately after surgery can help prevent chronic pain and the mental health issues that often follow.

PDF of article

Posted on

LSD reduces anxiety for 4 months

MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders

MindMed’s collaborators at University Hospital Basel studied the effect of two high doses of LSD (200μg) on patients with anxiety disorders.

They found that 65% of subjects had significant reductions in anxiety scores for 16 weeks after the treatments.

Like many other studies have found, mystical experiences were significantly correlated with long-term therapeutic benefits.

PDF of article

Posted on

Customized microdosing kits

Red Light Holland Files International Patent Application for ‘Find Your Dose’ Customization of Microdosing Kits Based on Biometric and Movement Data

Red Light Holland (TRIP) recently filed an international patent application for its “Find Your Dose” custom microdosing kits.

The kits help individuals get the most out of microdosing by providing personalized protocols based on biometric and movement data. 

This week, the company successfully imported 200 microdosing kits into Canada from the Netherlands with hopes that patients will be able to try microdosing through the Special Access Program.

PDF of article

Posted on

Understanding neurodiversity

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

COMPASS Pathways (CMPS) is funding a psilocybin study to better understand the brain science of neurodiversity.

Using brain imaging and behavioural tasks, researchers will investigate how psilocybin affects the serotonin brain networks in autistic adults compared to non-autistic adults. 

The goal is to understand the unique brain mechanisms associated with autism to provide “better tailored choices” to autistic people.

CMPS shares spiked 11% yesterday after the company announced Q1 financial results, including $21.2M net loss and $243.7M in cash.

PDF of article

Posted on

How ketamine affects the brain over time

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

The results from Cybin and Kernel’s brain imaging study are in!

The findings suggest that a single dose of ketamine has a lasting effect on the way information flows through the brain.

Subjects’ brain activity patterns were relatively stable for 5 days leading up to the ketamine session.

After a low dose of ketamine, there were significant changes in functional connectivity lasting at least 5 days. 

Top images: Johnson’s absolute functional connectivity for minutes 5-15 after he received the 57.75mg intramuscular injection of Ketamine. Bottom images: Johnson’s relative functional connectivity changes after the Ketamine took effect starting at minutes 15-25. (Graphic: Business Wire)

PDF of article

Posted on

Participate in psychedelic research

If you’ve been wanting to try psychedelic therapy legally, now’s your chance!

Johns Hopkins is recruiting participants for a number of psilocybin studies on:

Plus, Nova Mentis is recruiting both autisitc and neurotypical patients for an observational study that will lead to a psilocybin microdosing study.

If you want to contribute to psychedelic research from home, check out Johns Hopkins’ online surveys on psychedelics and breathwork for anxiety, depression, and PTSD.

Posted on

COMPASS announces new psilocybin therapy findings

COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression

New studies suggest that COMPASS Pathways’ proprietary psilocybin has promise in treating some of the most challenging mental health conditions: severe treatment-resistant depression and anorexia nervosa.

After a single dose of psilocybin, 58.3% of patients with severe treatment-resistant depression (meaning they’d tried 5+ antidepressant treatments without success) had a reduction in depression scores for 12 weeks.

One quarter of patients no longer qualified for a depression diagnosis.

In the anorexia study, 30% of patients had significant reductions in symptoms at the 1-month follow up, increasing to 40% at the 3-month follow up.

PDF of article

Posted on

Field Trip splits up

Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies

Field Trip Health (FTRP) is separating into two independent public companies. Its drug discovery division will become Reunion Neuroscience Inc. and its client care division will be renamed Field Trip Health and Wellness Ltd. The separation allows each company to establish distinct capital structures and management teams that are suited to their unique strategies.

PDF of article